Abstract

The aim of the present work was to set up an optimized protocol for human cerebrospinal fluid amyloid-β (Aβ) profiling. We devised an immunoproteomic assay that employs monoclonal antibodies (mAbs) on Preactivated Surface (PS20) chip array followed by SELDI TOF MS. A comparison of a number of factors was performed, and the impact of these differences was noted. Each variable was tested using in parallel two different mAbs, 6E10 and 4G8. In addition, we tested whether the combined use of these two mAbs could improve the capture of N and C-terminally truncated Aβ peptides and then the quality of spectra. The best results were obtained using a mixture of Aβ mAbs (0.125 μg/μL 6E10+4G8): 15 Aβ peptides (including 3 N-terminally truncated forms) were detected. This approach has many potential advantages in speed, sensitivity and economy of reagents and could be helpful in order to define the role played by specific Aβ truncated forms in cognitive decline.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.